Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01994954
Other study ID # IP00009772
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2013
Est. completion date February 2019

Study information

Verified date May 2023
Source University of Massachusetts, Worcester
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators hypothesize that Recorded Home Oximetry (RHO) utilization will not increase rates of respiratory-related re-hospitalizations and ED visits, and will not impair growth compared to standard oxygen management protocols. Evidence-based specific consensus guidelines for home regulated oxygen management do not currently exist. Current strategies for infants requiring outpatient supplemental home oxygen include brief checks of oxygen status during monthly clinic visits. Although the infants stay on monitors, no data in between visits is obtained to ensure that infants can maintain oxygen levels after weans are made. Before finally allowing oxygen to be removed, many centers also require an overnight sleep study in the hospital, to make sure that the infant's oxygen levels stay safe when the infant is in deep sleep. Because these methods rely solely on assumptions rather than individually recorded data, an infant's time on supplemental oxygen may be prolonged or insufficient. This study will evaluate both the currently used accepted therapy and a method of weaning that involves recording and sending oxygen data for analysis in between clinic visits. Premature infants who require home oxygen therapy at time of discharge who meet eligibility criteria will be randomized into two arms: Arm A ("Standard therapy"): Infants' oxygen will be increased, decreased, or maintained based on brief structured assessments during monthly clinic visits. Arm B (Recorded Home Oximetry (RHO)): Infants will have the same monthly clinic assessments as in Arm A, but also will utilize Recorded Home Oximetry (RHO) to potentially increase, decrease or maintain oxygen between monthly visits. Parents of all infants will be interviewed using structured quality-of-life questionnaires at the beginning and ending of the oxygen management process. Health care utilization (emergency department visits and rehospitalizations) and growth will be assessed 6 months after discontinuation of oxygen. The investigators overall objective is to determine whether Recorded Home Oximetry (RHO) can improve caregiver quality of life, and can shorten Home Oxygen Therapy (HOT) duration and eliminate need for polysomnogram, without compromising safety. The investigators will determine respiratory-related re-hospitalizations, emergency department (ED) visits, and growth parameters to confirm safety of the proposed weaning strategies.


Recruitment information / eligibility

Status Completed
Enrollment 196
Est. completion date February 2019
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender All
Age group N/A to 37 Weeks
Eligibility Inclusion Criteria: - Infant with birth gestational age = 37 (37 0/7) wks postmenstrual age (PMA) who has requirement for supplemental O2 at time of NICU discharge, as determined by primary NICU team. - Infant receiving pediatric pulmonology care at the Center for Healthy Infant Lung Development - Parent aged 18 years or older - English or Spanish-speaking. Exclusion Criteria: - Parents whose infants has presence of pulmonary hypertension at enrollment - Parents whose infant with syndrome or other diagnosis with known high risk for persistent hypoxia (cardiac disease, Trisomy 21, Pierre-Robin Sequence, etc.) - Parents whose infant has requirement for O2 flow rate > 1 L/min or tracheostomy - Any infants who also require caffeine at discharge from the NICU

Study Design


Related Conditions & MeSH terms


Intervention

Other:
RHO
Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.

Locations

Country Name City State
United States Boston Children's Hospital Boston Massachusetts
United States University of Vermont Medical Center Burlington Vermont
United States University of Connecticut Health Center Farmington Connecticut
United States Dartmouth Hitchcock Medical Center Lebanon New Hampshire
United States Kentucky Children's Hospital at University of Kentucky Lexington Kentucky
United States Baystate Medical Center Springfield Massachusetts
United States Boston Children's Hospital Physicians Valhalla New York
United States UMass Memorial Medical Center Worcester Massachusetts

Sponsors (11)

Lead Sponsor Collaborator
University of Massachusetts, Worcester Bay State Medical Center, Boston Children's Hospital, Connecticut Children's Medical Center, Dartmouth-Hitchcock Medical Center, Patient-Centered Outcomes Research Institute, Tufts Medical Center, UConn Health, University of Kentucky, University of Vermont Medical Center, Westchester Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Duration of Home Oxygen Therapy Duration of home oxygen use from time of randomization (baseline visit) to successful discontinuation of home oxygen therapy (HOT). NICU discharge date until successful discontinuation of home oxygen therapy (HOT), up to 26 months.
Primary Caregiver Quality of Life We will compare the difference between survey-derived quality-of-life scores, comparing parent response averages while on home oxygen therapy (HOT) versus 3 months post oxygen discontinuation scores in both arms. The infant scale is composed of 36 items comprising 5 dimensions. The item scaling is a 5-point Likert scale from 0 (never) to 4 (almost always). Scores range from 0 to 100, with a higher score indicating a higher parent satisfaction and quality of life. Monthly while on home oxygen therapy and at 3 months post discontinuation of therapy
Secondary Participants With Respiratory-related Emergency Department Visits and Rehospitalizations We will assess rates of rehospitalization or ED visit throughout the weaning process and continue to assess until 6 months post discontinuation. WIthin 6 months of discontinuation of home oxygen
Secondary Growth Parameters Growth measurements were taken at each monthly clinic visit while on oxygen. The average for weight z-score change was calculated for each subject while on oxygen therapy. After oxygen discontinuation, growth measurements were taken at the 1 month and 6 month post wean visits. These two measurements were again averaged for each patient. The weight z-score change was found in both arms for pre and post weaning from home oxygen therapy. The weight z-score indicates the number of standard deviations away from the mean a participants weight is. A z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. Enrollment to 6 months post home oxygen therapy discontinuation
Secondary Growth Parameters, Weight-for-length Z-score Change Growth measurements were taken at each monthly clinic visit while on oxygen. The average for weight for length z-score change was calculated for each subject while on oxygen therapy. After oxygen discontinuation, growth measurements were taken at the 1 month and 6 month post wean visits. These two measurements were again averaged for each patient. The weight for length z-score change was found in both arms for pre and post weaning from home oxygen therapy.The weight-for-length z-score indicates the number of standard deviations away from the mean a participants weight is. A z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. Enrollment through 6 months post discontinuation of home oxygen therapy
See also
  Status Clinical Trial Phase
Completed NCT02785926 - Impact of Antenatal Exposure to Pesticides on Neurophysiological Functions (Sleep, Respiration) of Preterm Neonates
Completed NCT01946971 - Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER) Phase 1/Phase 2
Completed NCT01530360 - Cerebral Oxygenation to Guide Medical Interventions in Extremely Preterm Infants Phase 1
Completed NCT00681018 - Feeding Study in Premature Infants N/A
Completed NCT00217191 - Ibuprofen and Renal Function in Premature Infants Phase 4
Completed NCT01077271 - Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA N/A
Completed NCT00282113 - Effects of Probiotic and Prebiotic Combinations on Premature Infants N/A
Active, not recruiting NCT02943746 - Targeted Protein Fortification in Extremely Low Birth Weight Preterm Infants N/A
Completed NCT00389909 - Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants Phase 4
Completed NCT00747591 - Urine Concentration of S100B in Extremely Premature Infants N/A
Recruiting NCT04555590 - Implementation of an Evidence Based Parentally Administered Intervention for Preterm Infants N/A
Completed NCT06352047 - The Effects of Positioning After Extubation of Preterm Infants on the Respiratory Functions N/A
Completed NCT03217045 - Nutrition Protocol and Premature Infants' Growth
Recruiting NCT03552952 - Development of Preterm Infant Gut Microbiome
Recruiting NCT06332521 - Infant Crying, a Bioacoustic Prognostic Signal for Neurodevelopment
Completed NCT04659083 - How NAVA Works in Preterm Infants With Irregular Respiratory Efforts
Completed NCT05807191 - The Effect of Using Clinical Guidelines on Kangaroo Care on Newborn and Maternal Outcomes N/A
Completed NCT03914690 - Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage Phase 2
Completed NCT01140243 - Infant Formula Supplemented With a Special Fat Formulation for Premature Infants Following Discharge From Hospital N/A
Completed NCT00957840 - Intraventricular Hemorrhage and Post Hemorrhagic Ventricular Dilation: Natural Course, Treatment, and Outcome N/A